ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVX vs AXSM // EV/EBITDA & P/E VALUATION

Abivax SA (NASDAQ) VS. Axsome Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ABVX 7 — AXSM 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVX VS. AXSM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVX AXSM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% -21.90% +31.80 ABVX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x — — TIE /valuation <GO>
Free Cash Flow Yield 2.21% -1.25% +3.46 ABVX /fcf-yield <GO>
Operating Margin 13.90% -26.10% +40.00 ABVX /operating-margins <GO>
Net Profit Margin 10.90% -28.70% +39.60 ABVX /net-margins <GO>
Revenue Growth (YoY) 8.80% 65.50% -56.70 AXSM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 5.34 -1.60 AXSM /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 ABVX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.0 25.9 +15.10 ABVX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 1.15 -0.10 AXSM /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 35.0x -4.50 ABVX /forward-pe <GO>
Enterprise Scale & Market Cap $7.56B $7.57B -$10.1M AXSM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVX REV AXSM REV ABVX GROSS % AXSM GROSS % ABVX FCF AXSM FCF
FY 2025 — $638.5M — — — -$93.9M
FY 2024 — $385.7M — — — -$128.7M
FY 2023 — $270.6M — — — -$157.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVX // BETA 1.05
AXSM // BETA 1.15